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Abstract Non-functioning pituitary adenoma (NFPA)
with higher proliferation index (WHO II) are often a
therapeutical challenge. Low somatostatin receptor
expression in these tumors usually prevents a treatment
with somatostatin analogs. In 1996, a 55-year-old patient
was referred due to right-sided headache. A pituitary
macroadenoma with infiltration into the right cavernous
sinus was diagnosed. There was no visual field deficit and
the clinical and biochemical work up was consistent with a
NFPA. The patient underwent transsphenoidal surgery.
Residual adenoma remained in the right cavernous sinus.
Histologically, a null-cell adenoma with a high prolifera-
tion index was documented (MIB-1: 11.6 %, WHO II).
Somatostatin receptor autoradiography was performed in
the surgical specimen showing a homogenous expression
of sst2 receptors. Radiosurgery was completed with stable
disease for 8 years. In 2004, the patient was diagnosed with
an incomplete palsy of the right oculomotorius nerve and a
significant increase in the volume of the adenoma in the
right cavernous sinus. After a positive Octreoscan the
patient consented to an experimental therapy approach
using Lutetium DOTATOC (3 9 200 mCi). The palsy of
the oculomotorius nerve improved and remained stable
until today (March 2013), the follow-up MRI scans
demonstrated stable disease. This is the first case of a
patient with a NFPA (WHO II) in whom PRRT success-
fully improved the local complications of the tumor for
more than 8 years after ineffective surgery and gamma
knife therapy. The determination of sst2 in vitro using
autoradiography and in vivo by Octreoscan was instru-
mental to administer this therapy in a challenging situation.
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Introduction
Peptide receptor radionuclide therapy (PRRT) with radio-
labeled somatostatin analogues (i.e. 90Y-DOTATOC,
177Lu-DOTATATE) has been shown to be an effective tool
in treating metastasized gut neuroendocrine tumors (NET)
[1, 2]. These gut NET are characterized by the presence of
a high number of somatostatin receptor subtype 2 (sst2) that
are distributed on the tumor cell membranes [3], and are
the molecular basis for therapy with somatostatin analogs.
Tumoral sst2 can be detected not only in vivo by an Oct-
reoscan [4] but also in vitro by receptor autoradiography
[5] or recently by immunohistochemistry [6].
In pituitary GH- [7], TSH- [8, 9] and ACTH-secreting
tumors [10], PRRT with radiolabeled somatostatin analogs
is rarely chosen. Instead, non-radioactive somatostatin
analogues (octreotide, lanreotide) are established in inhib-
iting hormone secretion and—in part—growth of these
tumors, the effectiveness of the therapy being dependent on
the receptor expression. In non-functioning pituitary ade-
noma (NFPA), the therapy is primarily surgical rather than
octreotide or PRRT, in particular since the somatostatin
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receptors of the sst2 subtype are much less frequently
expressed [3, 11, 12]. In pituitary NFPA with higher pro-
liferation index (WHO II), a type of tumor which is often a
therapeutical challenge, data on sst2 status are virtually
missing.
In this paper we report for the first time of a patient with
a NFPA WHO II and severe ocular manifestations, who
had a tumor with high density of sst2 which could be
brought under control for over 8 years, after a PRRT with
radiolabeled somatostatin analogs was performed.
Case report
In 1996, a 56 years old patient was referred for brain MRI
scan due to new severe right-sided headache. A pituitary
macroadenoma with infiltration into the right cavernous
sinus and extending to the optic chiasm was diagnosed.
There was no visual field deficit at the time and the clinical
and biochemical work up was consistent with a NFPA
without pituitary deficiencies.
In October 1996 the patient underwent successful trans-
sphenoidal surgery. Residual adenoma remained in the right
cavernous sinus which was impossible to remove (Fig. 1a).
A fat pad was introduced between the intact pituitary gland
on the left side and the right cavernous sinus. This allowed
for protecting the functioning pituitary gland from the
planned radiotherapy. Histologically, a null-cell adenoma
with a high proliferation index was documented (MIB-1:
11.6 %) consistent with a pituitary adenoma WHO II.
Additionally, at that early stage of disease, somatostatin
receptor autoradiography (125I-Tyr3-Octreotide) was per-
formed that showed a homogenous expression of sst2
receptors in high density in the adenoma (Fig. 2A).
In November 1996 radiosurgery was performed for the
residual tumor using gamma knife (dose 50 Gy). No pitu-
itary insufficiencies ensued and visual fields and opthal-
mological examination were normal.
Follow-up MRI scans in 1997 and 1999 showed stable
residual adenoma, in 2001 even a reduction of the residual
tumor was detected and the patient renounced further
neuroradiological follow-up.
In 2004, the patient was investigated following an acute
decrease in visual acuity with additional double images in
the horizontal axis. In addition, incomplete ptosis of the
right eyelid and right eye mydriasis was evident suggesting
oculomotor nerve palsy (Fig. 3). MRI scan demonstrated a
significant increase in the volume of the adenoma in the
Fig. 1 Contrast coronal magnetic resonance imaging (T1WI) after
transsphenoidal surgery in 1996 (a) and at the time of N. oculomo-
torius palsy in 2004 (b). Following surgery there is residual tumor
within the sinus cavernosus right (a arrow) and the remaining intact
pituitary gland is on the left. During follow-up residual tumor within
the sinus cavernosus right increases in size resulting in N. oculomo-
torius palsy (b arrow). Last magnetic resonance imaging in 2011
showing stable residual mass in the right sinus cavernosus (c arrow)
b
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right cavernous sinus (Fig. 1b) indicating that the opthal-
mological symptoms were related to a progression of the
adenoma. A second surgical intervention was impossible
and an additional radiotherapy carried a significant risk for
side effects. Due to the known high expression of sst2 in the
adenoma the patient consented to an experimental therapy
approach using PPRT with Lutetium DOTATOC and—
after a positive OctreoscanTM (Fig. 2B)—PRRT was suc-
cessfully administered in 2005 (3 9 200 mCi). The palsy
of the oculomotorius nerve improved, the follow-up MRI
scans demonstrated stable disease up to now (March 2013)
and the pituitary function remained intact.
Discussion
To our knowledge this is the first case of a patient with a
NFPA (WHO II) in whom PRRT successfully stabilized
and improved the local complications of the tumor after
ineffective surgery and gamma knife therapy. The deter-
mination of sst2 in vitro using autoradiography and in vivo
by Octreoscan was instrumental to administer this experi-
mental therapy in a clinically challenging situation.
While the therapeutical effect of somatostatin analogues
in controlling autonomous endocrine secretion and induc-
ing GH-adenoma shrinking is well established [7, 9, 10, 13,
14] the effectiveness of somatostatin analogues on local
tumor control in patients with NFPA, is less evident: not
only is the sst2 expression much lower than in other pitu-
itary tumors [3, 11] but also the octreotide effect is much
more difficult to assess due to the lack of a reliable hor-
monal parameter. Moreover, surgery and—if needed—
radiotherapy is usually capable to control the disease in the
vast majority of patients. Several uncontrolled short-term
studies (3–12 months) indicate that somatostatin analogues
may stabilize residual tumor size in NFPA but do not
induce significant tumor shrinkage [15–18]. One recent
prospective study over 3 years assessed the effect of
octreotide LAR on progression in NFPA with postopera-
tively residual tumor and suggest an effect on stabilization
but not on shrinkage [19].
PRRT—a targeted radiotherapy—results in a stabiliza-
tion of the disease with regard to secretion (if present) and
growth [1, 2] in metastasized gut neuroendocrine tumors
[1, 2] that are well known to contain sst2 in high density.
Because PRRT in these tumors is known to induce per-
sisting side-effects (renal failure, bone marrow toxicity
[2]), the indication for therapy has to be carefully discussed
on the basis of somatostatin receptor status. No PRRT
study with long-term follow-up in NFPA has been pub-
lished. Two recent communications reported the efficacy
and safety of PRRT in a patient with pituitary metastasis of
a NET [20] and in a patient with a giant prolactin secreting
tumor resistant to dopamine-agonists [21], but the follow-up
Fig. 2 A sst2 receptor determinations in vitro in the pituitary
adenoma of the patient. a Hematoxylin-eosin-stained tumor tissue.
b Autoradiogram showing total binding of 125I-Tyr3-octreotide in
the pituitary adenoma. The whole tumor is strongly positive.
c Autoradiogram showing nonspecific binding of 125I-Tyr3-octreotide
in the presence of cold octreotide (10-6 M). B Octreoscan in a
patient with a non-functioning pituitary adenoma (WHO II) showing
intense uptake in the region of the pituitary
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of the two cases was less than 2 years and the somatostatin
receptor profile had not been analyzed in vitro before
therapy.
The present tumor presented on one hand with a high
density of sst2 and, on histology, with an elevated mitotic
index consisting with an atypical pituitary adenoma (WHO
II). In the German pituitary registry atypical adenoma
account for 2.7 % of all registered pituitary neoplasms and
the null cell adenomas were amongst the most frequent
type [22]. Some evidence suggests that atypical adenomas
have a poorer prognosis that may be related to a higher
degree of local invasiveness, larger size and accelerated
growth as shown in the present case. In such challenging
cases an additional therapeutical strategy based on targeted
radiotherapy may be helpful in controlling the disease.
Personalized medicine is a new therapeutical strategy in
oncology that considers molecular targets of the tumors
into the treatment regime [23]. The present case may
impressively support the concept that personalized
medicine should be discussed in endocrine patients, at least
in those who present with a challenging course of their
disease such as NFPA (WHO II). A prerequisite is the
availability of a simple way to reliably measure somato-
statin receptors in vitro within the tumor sample in order to
have a molecular rationale for PRRT. Eight years ago the
rather complex and costly receptor autoradiography tech-
nique was used to analyze sst receptors in this patient
because no satisfactory alternative existed. An sst2 anti-
body has recently been developed that can, alternatively, be
employed in future to detect sst2 immunohistochemically
on formalin-fixed tissue [6]. This will simplify the thera-
peutical strategy in challenging cases and may contribute to
a personalized medicine in endocrinology.
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